证券代码：301108 证券简称：洁雅股份 公告编号：2025-054 铜陵洁雅生物科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 铜陵洁雅生物科技股份有限公司（以下简称"公司"或"洁雅股份"）于 2025 年 7 月 21 日召开第六届董事会第二次会议，审议通过了《关于为参股公司提供担 保暨关联交易的议案》。本事项已经公司独立董事专门会议审议通过。 根据业务发展需要，公司参股公司赛得利（铜陵）无纺材料有限公司（以下 简称"赛得利铜陵"）拟向银行申请总额度为 3000 万元的贷款，贷款期限为三年。 公司及其他各方股东拟按各自持股比例提供担保，公司持有赛得利铜陵 20%的股 权，赛得利（九江）纤维有限公司（以下简称"赛得利九江"）持有赛得利铜陵 式为连带责任担保，担保期限以与银行签署的协议为准，其余股东按照持股比例 为赛得利铜陵提供担保。 公司董事长兼总经理蔡英传先生在赛得利铜陵担任董事，公司董事兼财务总 监杨凡龙先生在赛得利铜陵担任监事。根据《深圳证券交易所创业板股票上市规 则》的规定，赛得利铜陵为公司的关联法人。本次公司与 ...

Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms that Tongling Jieya Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, adhering to relevant laws and regulations [1][3][29]. Group 1: Company Background - Tongling Jieya Biotechnology Co., Ltd. is a legally established and validly existing listed company, having been registered in December 2008 and listed on the Shenzhen Stock Exchange's Growth Enterprise Market [3][4]. - The company holds a business license issued by the Market Supervision Administration of Tongling City, with a unified social credit code [4]. Group 2: Incentive Plan Overview - The purpose of the 2025 restricted stock incentive plan is to establish a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][10]. - The plan involves granting a total of 1.82 million restricted shares, accounting for 1.62% of the company's total share capital as of the announcement date [9][10]. Group 3: Eligibility and Conditions - The incentive plan specifies that eligible participants include directors, senior management, and other personnel deemed necessary for motivation, excluding independent directors and certain major shareholders [6][8]. - The plan outlines specific conditions under which restricted shares can be granted and vested, including performance targets based on revenue growth rates for the years 2025 to 2027 [18][19]. Group 4: Granting and Vesting Details - The initial grant price for the restricted shares is set at 12.63 yuan per share, which is compliant with the stipulated pricing regulations [15][29]. - The vesting schedule includes multiple phases, with specific percentages of shares vesting after designated periods, contingent upon meeting performance criteria [12][19]. Group 5: Adjustments and Procedures - The plan includes provisions for adjustments to the number and price of restricted shares in the event of corporate actions such as stock splits or capital increases [20][22]. - The implementation of the incentive plan requires approval from the board of directors and the shareholders' meeting, with specific procedures for public disclosure and compliance with legal requirements [23][24].

Summary of Key Points from the Conference Call of Jieya Co., Ltd. Company Overview - Jieya Co., Ltd. is benefiting from Kimberly-Clark's strategic adjustments in the European market, with expected new orders in 2025 bringing nearly 200 million RMB in sales [2][6] - The company is actively expanding its business in Australia, New Zealand, Southeast Asia, and Latin America, indicating significant growth in international markets [2] Core Business Developments - Jieya has secured a project with Procter & Gamble in the Canadian market, with an expected annual sales of approximately 30 million RMB, potentially increasing to nearly 100 million RMB [2][8] - The new factory in North Carolina, USA, originally planned to start production in 2025, has been delayed to Q1 2026 due to approval and client review factors, with a designed capacity of 100 million USD [2][11] - In the first half of 2025, Jieya's revenue growth is expected to be around 10%, with better profit growth anticipated, and a faster growth rate expected in the second half of the year [2][15] Client and Market Structure - Jieya primarily serves major international brands such as Johnson & Johnson, Kimberly-Clark, Procter & Gamble, L'Oréal, and Australia's largest supermarket chain, Woolworths [4] - The company's business structure is heavily focused on wet wipes, which constitute the majority of its offerings, while cosmetics account for about 10% of overall business [4] Financial Performance and Projections - In Q1 2025, Jieya reported a slight decline in performance, but a recovery is expected in Q2 due to new orders, with overall performance showing improvement [3][15] - The company has a strong financial reserve of approximately 1.3 billion RMB, sufficient to support business expansion [5][30] Strategic Partnerships and Market Trends - The strategic shift by Kimberly-Clark to outsource production has created opportunities for Jieya, with a significant increase in orders expected [7] - The wet wipes industry is facing increased competition from new entrants, but major players like Jieya focus on their market shares without significant conflict [17] Future Growth and Investment Plans - Jieya aims to explore international market opportunities and product categories as key growth drivers, with plans to maintain stable growth in core business areas [13][14] - The company is considering investments and acquisitions to seek business growth, particularly targeting brand collaborations [24] Challenges and Risks - The company faces challenges in the cosmetics sector due to reduced orders from L'Oréal, but it plans to continue serving L'Oréal while expanding domestic client relationships [5][23] - There are uncertainties regarding the production timeline of the new factory in the USA, which could impact future revenue [11][20] Export and Domestic Sales Dynamics - Jieya's export ratio is expected to increase from 50% in 2024 to 70% in 2025, while domestic sales are projected to decrease to 30% [27] Profitability Outlook - The gross margin is projected to improve as international business grows, with current margins around 20%-25% for international operations and about 10% for domestic [28] Conclusion - Jieya Co., Ltd. is positioned for growth through strategic partnerships, international market expansion, and a focus on core competencies in wet wipes, while navigating challenges in the cosmetics sector and maintaining a strong financial foundation [31]

Group 1: Company Overview - Tongling Jeya Biotechnology Co., Ltd. specializes in the research, production, and sales of wet wipes, with over 20 years of industry experience [1][2] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 3, 2021 [2] Group 2: Financial Performance - In the first quarter of 2025, the company reported a revenue of 124 million yuan and a net profit of 1,006.27 million yuan [3] Group 3: Key Clients and Market Expansion - Major clients for the wet wipes business include international brands such as Woolworths, Kimberly-Clark, Johnson & Johnson, and Procter & Gamble, as well as domestic e-commerce brands like babycare and Dongfang Zhenxuan [3] - The company has seen a stable order flow from existing clients and has successfully secured new business in Europe and Canada [3] Group 4: U.S. Factory Development - The company acquired a wet wipes factory in the U.S. this year, currently undergoing renovations and equipment installation, with production expected to start in Q1 2026 [3] - Risks associated with the U.S. factory include uncertainties in renovation and approval processes, client audits, potential delays in production, and cultural differences affecting efficiency [3] Group 5: Brand Development and Other Ventures - The company's efforts to develop its own brand through fund incubation have not met expectations, leading to a significant reduction in investment [3] - The joint venture with Jiangsu Chuangjian for collagen products has not made substantial progress due to rapid market changes [3] Group 6: Compliance and Regulations - The investor communication activity adhered to the Shenzhen Stock Exchange's self-regulatory guidelines, ensuring no significant undisclosed information was leaked [4]

证券代码：301108 证券简称：洁雅股份 公告编号：2025-054 关于为参股公司提供担保暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 铜陵洁雅生物科技股份有限公司（以下简称"公司"或"洁雅股份"）于 2025 年 7 月 21 日召开第六届董事会第二次会议，审议通过了《关于为参股公司提供担 保暨关联交易的议案》。本事项已经公司独立董事专门会议审议通过。 根据业务发展需要，公司参股公司赛得利（铜陵）无纺材料有限公司（以下 简称"赛得利铜陵"）拟向银行申请总额度为 3000 万元的贷款，贷款期限为三年。 公司及其他各方股东拟按各自持股比例提供担保，公司持有赛得利铜陵 20%的股 权，赛得利（九江）纤维有限公司（以下简称"赛得利九江"）持有赛得利铜陵 80%的股权。公司拟按持股比例为赛得利铜陵提供 600 万元的最高额担保，担保方 式为连带责任担保，担保期限以与银行签署的协议为准，其余股东按照持股比例 为赛得利铜陵提供担保。 公司董事长兼总经理蔡英传先生在赛得利铜陵担任董事，公司董事兼财务总 监杨凡龙先生在赛得利铜陵担任监 ...

证券代码：301108 证券简称：洁雅股份 公告编号：2025-055 铜陵洁雅生物科技股份有限公司 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 铜陵洁雅生物科技股份有限公司（以下简称"公司"）第六届董事会第二次 会议审议通过了《关于召开 2025 年第四次临时股东会的议案》，决定于 2025 年 8 月 8 日（星期五）召开公司 2025 年第四次临时股东会，现将本次股东会的 有关事项通知如下： 一、召开会议的基本情况 1. 股东会届次：2025 年第四次临时股东会。 2. 股东会的召集人：公司董事会。 3. 会议召开的合法、合规性：本次股东会的召集和召开符合有关法律、行 政法规、部门规章、规范性文件及《公司章程》的规定和要求。 4. 会议召开的日期、时间： （1）现场会议召开时间：2025 年 8 月 8 日（星期五）14:30。 （2）网络投票时间：2025 年 8 月 8 日（星期五）。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 8 月 8 日 9:15-9:25，9:30 ...

一、董事会会议召开情况 铜陵洁雅生物科技股份有限公司（以下简称"公司"）第六届董事会第二次 会议于 2025 年 7 月 21 日以通讯方式召开，本次会议的通知已于 2025 年 7 月 18 日通过电子邮件的方式送达全体董事。本次会议应出席董事 9 人，实际出席董事 9 人（全体董事以通讯表决方式出席）。本次会议由董事长兼总经理蔡英传先生 主持，公司高级管理人员列席本次会议。本次董事会会议的召开符合《中华人民 共和国公司法》等有关法律、行政法规、部门规章、规范性文件及《公司章程》 的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 1、审议通过《关于〈铜陵洁雅生物科技股份有限公司 2025 年限制性股票 激励计划（草案）〉及其摘要的议案》 证券代码：301108 证券简称：洁雅股份 公告编号：2025-053 铜陵洁雅生物科技股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为了进一步建立、健全公司长效激励与约束机制，吸引和留住优秀人才，扩 大激励对象覆盖面，强化激励效果，促进公司长期稳定发展，公 ...

二、董事会认为需要激励的其他人员名单 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 冯磊 | 董事会认为需要激励的其他人员 | | 2 | 袁先国 | 董事会认为需要激励的其他人员 | | 3 | 朱怀河 | 董事会认为需要激励的其他人员 | | 4 | 章俊强 | 董事会认为需要激励的其他人员 | | 5 | 汪婷 | 董事会认为需要激励的其他人员 | | 6 | 冯旭飞 | 董事会认为需要激励的其他人员 | 铜陵洁雅生物科技股份有限公司 2025 年限制性股票激励计划首次授予部分激励对象名单 | 一、 本激励计划授予的限制性股票在各激励对象间的分配情况如下表所示： | | --- | | 序号 姓名 | | 国籍 | 职务 | 获授予的权益 数量（万股） | 占授予权益 总数的比例 | 占本激励计划 公告日公司股 | | --- | --- | --- | --- | --- | --- | --- | | 一、董事、高级管理人员 | | | | | | 本总额的比例 | | 1 | 胡能华 | 中国 | 副总经理、董事会秘书 | 18.2 | 10% | 0.16 ...

证券简称：洁雅股份 证券代码：301108 铜陵洁雅生物科技股份有限公司 2025 年限制性股票激励计划（草案） 声 明 本公司及全体董事保证本激励计划及其摘要不存在虚假记载、误导性陈述或 重大遗漏，并对其真实性、准确性和完整性承担个别和连带的法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或行使权益安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励计划 所获得的全部利益返还公司。 - 2 - 铜陵洁雅生物科技股份有限公司 2025 年限制性股票激励计划 （草案） 二〇二五年七月 铜陵洁雅生物科技股份有限公司 2025 年限制性股票激励计划（草案） 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所创业板上市公司自律监管指南第 1 号——业务办理》和其他有关法律、 法规、规范性文件，以及《铜陵洁雅生物科技股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）。 ...

铜陵洁雅生物科技股份有限公司 本公司保证所填写的情况真实、准确、完整、合法，并承担因所填写情况有误所 产生的一切法律责任。 铜陵洁雅生物科技股份有限公司董事会 2025 年 7 月 21 日 2025 年限制性股票激励计划自查表 | | 公司简称：洁雅股份 股票代码：301108 | 独立财务顾问：无 | | | --- | --- | --- | --- | | 序号 | 事项 | 是否存在该 事项（是/否/ | 备注 | | | | 不适用） | | | | 上市公司合规性要求 | | | | 1 | 最近一个会计年度财务会计报告是否被注册会计师出具否定意 | 否 | | | | 见或者无法表示意见的审计报告 | | | | 2 | 最近一个会计年度财务报告内部控制被注册会计师出具否定意 | 否 | | | | 见或者无法表示意见的审计报告 | | | | 3 | 上市后最近 个月内出现过未按法律法规、公司章程、公开承 36 | 否 | | | | 诺进行利润分配的情形 | | | | 4 | 是否存在其他不适宜实施股权激励的情形 | 否 | | | 5 | 是否已经建立绩效考核体系和考核办法 | 是 | ...